ES2179040T3 - Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b. - Google Patents

Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.

Info

Publication number
ES2179040T3
ES2179040T3 ES92906520T ES92906520T ES2179040T3 ES 2179040 T3 ES2179040 T3 ES 2179040T3 ES 92906520 T ES92906520 T ES 92906520T ES 92906520 T ES92906520 T ES 92906520T ES 2179040 T3 ES2179040 T3 ES 2179040T3
Authority
ES
Spain
Prior art keywords
hepatitis
treatment
thiacitidine
desoxi
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906520T
Other languages
English (en)
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeg Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104741A external-priority patent/GB9104741D0/en
Priority claimed from GB919109505A external-priority patent/GB9109505D0/en
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of ES2179040T3 publication Critical patent/ES2179040T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCUBRE EL USO DE UN ANALOGO DE 1,3 EOSIDO Y DERIVADOS FARMACEUTICAMENTE ACEPTABLES DE EL PARA EL TRATAMIENTO DE INFECCIONES VIRICAS DE HEPATITIS B. TAMBIEN SE PROVEEN FORMULACIONES FARMACEUTICAS.
ES92906520T 1991-03-06 1992-03-05 Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b. Expired - Lifetime ES2179040T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919104741A GB9104741D0 (en) 1991-03-06 1991-03-06 Therapeutic nucleosides
GB919109505A GB9109505D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides

Publications (1)

Publication Number Publication Date
ES2179040T3 true ES2179040T3 (es) 2003-01-16

Family

ID=26298535

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01202860T Expired - Lifetime ES2286072T3 (es) 1991-03-06 1992-03-05 Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.
ES92906520T Expired - Lifetime ES2179040T3 (es) 1991-03-06 1992-03-05 Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01202860T Expired - Lifetime ES2286072T3 (es) 1991-03-06 1992-03-05 Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.

Country Status (21)

Country Link
EP (3) EP1142891B1 (es)
JP (5) JP3479068B2 (es)
KR (1) KR100270806B1 (es)
AT (2) ATE361293T1 (es)
AU (1) AU662130B2 (es)
CA (1) CA2105486C (es)
CZ (1) CZ282747B6 (es)
DE (2) DE69232649T2 (es)
DK (2) DK1142891T3 (es)
ES (2) ES2286072T3 (es)
HU (1) HUT64844A (es)
IE (1) IE920701A1 (es)
IL (1) IL101144A (es)
MX (1) MX9203213A (es)
NZ (1) NZ264621A (es)
PT (1) PT100198B (es)
RU (1) RU2116789C1 (es)
SK (1) SK279542B6 (es)
TW (1) TW201268B (es)
UA (1) UA54364C2 (es)
WO (1) WO1992015308A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226137B1 (en) * 1989-02-08 2008-05-28 Shire Canada Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US6346627B1 (en) * 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
EP1142891B1 (en) * 1991-03-06 2007-05-02 Emory University Salts and amides of (-)cis 5-Fluoro-2'-deoxy-3'-thiacytidine useful for the treatment of hepatitis B
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
CA2637774C (en) * 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
WO1996040164A1 (en) 1995-06-07 1996-12-19 Emory University Nucleosides with anti-hepatitis b virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EP0970078B1 (en) * 1997-03-19 2004-05-19 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
EP2415776B1 (en) 1998-08-10 2016-05-25 Novartis AG Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
EP1104415B1 (en) 1998-08-12 2004-11-10 Gilead Sciences, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1387850A2 (en) 2001-05-18 2004-02-11 Rakesh Kumar Antiviral nucleosides
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
WO2004024095A2 (en) 2002-09-13 2004-03-25 Idenix (Cayman) Limited ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
KR101950635B1 (ko) * 2008-06-30 2019-05-20 토카겐 인크. 5-플루오르시토신 제제 및 이의 용도
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK224286A (da) * 1985-05-15 1986-11-16 Wellcome Found 2',3'-dideoxy-nucleosider
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
EP1142891B1 (en) * 1991-03-06 2007-05-02 Emory University Salts and amides of (-)cis 5-Fluoro-2'-deoxy-3'-thiacytidine useful for the treatment of hepatitis B

Also Published As

Publication number Publication date
SK279542B6 (sk) 1998-12-02
JP3479068B2 (ja) 2003-12-15
CA2105486A1 (en) 1992-09-07
EP1142891A1 (en) 2001-10-10
JP2011102308A (ja) 2011-05-26
ATE361293T1 (de) 2007-05-15
CA2105486C (en) 2003-10-28
JPH06505725A (ja) 1994-06-30
DE69232649D1 (de) 2002-07-25
AU1367692A (en) 1992-10-06
EP1808434A2 (en) 2007-07-18
HUT64844A (en) 1994-03-28
DK0574487T3 (da) 2002-10-14
ES2286072T3 (es) 2007-12-01
JP2010013466A (ja) 2010-01-21
PT100198A (pt) 1993-05-31
WO1992015308A1 (en) 1992-09-17
IE920701A1 (en) 1992-09-09
CZ282747B6 (cs) 1997-09-17
DE69232649T2 (de) 2002-11-28
AU662130B2 (en) 1995-08-24
DK1142891T3 (da) 2007-08-27
EP0574487A1 (en) 1993-12-22
JP2007246536A (ja) 2007-09-27
UA54364C2 (uk) 2003-03-17
EP1808434A3 (en) 2008-04-02
EP0574487B1 (en) 2002-06-19
HU9302493D0 (en) 1993-11-29
TW201268B (es) 1993-03-01
JP4399478B2 (ja) 2010-01-13
RU2116789C1 (ru) 1998-08-10
SK95093A3 (en) 1994-04-06
KR100270806B1 (ko) 2000-11-01
CZ183593A3 (en) 1994-04-13
EP1142891B1 (en) 2007-05-02
DE69233693D1 (de) 2007-06-14
IL101144A0 (en) 1992-11-15
JP4891435B2 (ja) 2012-03-07
JP2002220388A (ja) 2002-08-09
JP3987335B2 (ja) 2007-10-10
NZ264621A (en) 1997-09-22
DE69233693T2 (de) 2008-01-24
ATE219366T1 (de) 2002-07-15
PT100198B (pt) 2000-03-31
IL101144A (en) 1996-09-12
IE20040402A1 (en) 2007-10-17
MX9203213A (es) 1992-07-01

Similar Documents

Publication Publication Date Title
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
EE02995B1 (et) 1,3-oksatiolaannukleosiidi analoogide kasutamine hepatiit B ravimpreparaatide valmistamiseks
ATE131730T1 (de) Nukleosidanalogen enthaltende antiviren- zubereitungen
MX9204474A (es) Analogos nucleosidos 1,3-oxatiolano.
DK224286A (da) 2',3'-dideoxy-nucleosider
IL101836A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives
MY109796A (en) 1,3-oxathiolane nucleoside analogues.
RU93043875A (ru) 1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения
ITMI931522A0 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
MY127808A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
MY137298A (en) Therapeutic nucleosides
DK0388049T3 (da) Penciclovirderivater til behandling af hepatitis B infektioner
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b
SE9602262D0 (sv) New use of derivatives of cystine